# Amgen quarterly revenue

entity: /record/amgen.md  
predicate: quarterly_revenue  
page: /record/amgen/quarterly_revenue  
as_of: 2026-11-09  
cite: AsOf. "Amgen quarterly revenue: 10,365,000,000 United States dollar", as of 2026-09-30. Claim clm_985DF46177C9, https://asof.is/claim/clm_985DF46177C9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.  

As of November 9, 2026, Amgen's quarterly revenue on the AsOf record is $10.37 billion, dated September 30, 2026, from a primary source (sec.gov).

56 claims on Amgen's quarterly revenue, 1 open and 55 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted.

## Current quarterly revenue

What the record asserts on 2026-11-09.

- [Amgen](/record/amgen.md) | quarterly_revenue | 10,365,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_985DF46177C9](/claim/clm_985DF46177C9.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm

## Every dated value

One claim per line, oldest first. Superseded claims stay visible.

- [Amgen](/record/amgen.md) | quarterly_revenue | 3,764,000,000 United States dollar | valid 2008-06-30 to 2008-09-30 | conf 0.95 | superseded | superseded_by [clm_D6A6F66C922D](/claim/clm_D6A6F66C922D.md) | [clm_17341E32AFF6](/claim/clm_17341E32AFF6.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,875,000,000 United States dollar | valid 2008-09-30 to 2009-03-31 | conf 0.95 | superseded | superseded_by [clm_E30E52778B73](/claim/clm_E30E52778B73.md) | [clm_D6A6F66C922D](/claim/clm_D6A6F66C922D.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,308,000,000 United States dollar | valid 2009-03-31 to 2009-06-30 | conf 0.95 | superseded | superseded_by [clm_C0FD4A4DBDE5](/claim/clm_C0FD4A4DBDE5.md) | [clm_E30E52778B73](/claim/clm_E30E52778B73.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,713,000,000 United States dollar | valid 2009-06-30 to 2009-09-30 | conf 0.95 | superseded | superseded_by [clm_AC30B5A349EC](/claim/clm_AC30B5A349EC.md) | [clm_C0FD4A4DBDE5](/claim/clm_C0FD4A4DBDE5.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,812,000,000 United States dollar | valid 2009-09-30 to 2010-03-31 | conf 0.95 | superseded | superseded_by [clm_0468DD568B92](/claim/clm_0468DD568B92.md) | [clm_AC30B5A349EC](/claim/clm_AC30B5A349EC.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,592,000,000 United States dollar | valid 2010-03-31 to 2010-06-30 | conf 0.95 | superseded | superseded_by [clm_623DCF66B2AC](/claim/clm_623DCF66B2AC.md) | [clm_0468DD568B92](/claim/clm_0468DD568B92.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,804,000,000 United States dollar | valid 2010-06-30 to 2010-09-30 | conf 0.95 | superseded | superseded_by [clm_1E3DCB2075FA](/claim/clm_1E3DCB2075FA.md) | [clm_623DCF66B2AC](/claim/clm_623DCF66B2AC.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000095012310074870/0000950123-10-074870-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,816,000,000 United States dollar | valid 2010-09-30 to 2011-03-31 | conf 0.95 | superseded | superseded_by [clm_5C7EB0130754](/claim/clm_5C7EB0130754.md) | [clm_1E3DCB2075FA](/claim/clm_1E3DCB2075FA.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000095012310102391/0000950123-10-102391-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,706,000,000 United States dollar | valid 2011-03-31 to 2011-06-30 | conf 0.95 | superseded | superseded_by [clm_5FE67E316722](/claim/clm_5FE67E316722.md) | [clm_5C7EB0130754](/claim/clm_5C7EB0130754.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000095012311048073/0000950123-11-048073-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,959,000,000 United States dollar | valid 2011-06-30 to 2011-09-30 | conf 0.95 | superseded | superseded_by [clm_296C33E5B63E](/claim/clm_296C33E5B63E.md) | [clm_5FE67E316722](/claim/clm_5FE67E316722.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000095012311074348/0000950123-11-074348-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 3,944,000,000 United States dollar | valid 2011-09-30 to 2012-03-31 | conf 0.95 | superseded | superseded_by [clm_2763B8997D8B](/claim/clm_2763B8997D8B.md) | [clm_296C33E5B63E](/claim/clm_296C33E5B63E.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000119312511296147/0001193125-11-296147-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 4,048,000,000 United States dollar | valid 2012-03-31 to 2012-06-30 | conf 0.95 | superseded | superseded_by [clm_D4DC1453EF41](/claim/clm_D4DC1453EF41.md) | [clm_2763B8997D8B](/claim/clm_2763B8997D8B.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/0001193125-12-216282-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 4,477,000,000 United States dollar | valid 2012-06-30 to 2012-09-30 | conf 0.95 | superseded | superseded_by [clm_5BA2730341DC](/claim/clm_5BA2730341DC.md) | [clm_D4DC1453EF41](/claim/clm_D4DC1453EF41.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000119312512344279/0001193125-12-344279-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 4,319,000,000 United States dollar | valid 2012-09-30 to 2013-03-31 | conf 0.95 | superseded | superseded_by [clm_4DC2460750E0](/claim/clm_4DC2460750E0.md) | [clm_5BA2730341DC](/claim/clm_5BA2730341DC.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000144530512003469/0001445305-12-003469-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 4,238,000,000 United States dollar | valid 2013-03-31 to 2013-06-30 | conf 0.95 | superseded | superseded_by [clm_B14B41207FDF](/claim/clm_B14B41207FDF.md) | [clm_4DC2460750E0](/claim/clm_4DC2460750E0.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000144530513001107/0001445305-13-001107-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 4,679,000,000 United States dollar | valid 2013-06-30 to 2013-09-30 | conf 0.95 | superseded | superseded_by [clm_3033018610D0](/claim/clm_3033018610D0.md) | [clm_B14B41207FDF](/claim/clm_B14B41207FDF.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815413000008/0000318154-13-000008-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 4,748,000,000 United States dollar | valid 2013-09-30 to 2014-03-31 | conf 0.95 | superseded | superseded_by [clm_4A26C5460842](/claim/clm_4A26C5460842.md) | [clm_3033018610D0](/claim/clm_3033018610D0.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815413000012/0000318154-13-000012-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 4,521,000,000 United States dollar | valid 2014-03-31 to 2014-06-30 | conf 0.95 | superseded | superseded_by [clm_F203C4084F80](/claim/clm_F203C4084F80.md) | [clm_4A26C5460842](/claim/clm_4A26C5460842.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815414000008/0000318154-14-000008-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,180,000,000 United States dollar | valid 2014-06-30 to 2014-09-30 | conf 0.95 | superseded | superseded_by [clm_FE2BDD289F38](/claim/clm_FE2BDD289F38.md) | [clm_F203C4084F80](/claim/clm_F203C4084F80.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815414000017/0000318154-14-000017-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,031,000,000 United States dollar | valid 2014-09-30 to 2015-03-31 | conf 0.95 | superseded | superseded_by [clm_C0A999C2E5DE](/claim/clm_C0A999C2E5DE.md) | [clm_FE2BDD289F38](/claim/clm_FE2BDD289F38.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815414000022/0000318154-14-000022-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,033,000,000 United States dollar | valid 2015-03-31 to 2015-06-30 | conf 0.95 | superseded | superseded_by [clm_28F3330C360C](/claim/clm_28F3330C360C.md) | [clm_C0A999C2E5DE](/claim/clm_C0A999C2E5DE.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815415000010/0000318154-15-000010-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,370,000,000 United States dollar | valid 2015-06-30 to 2015-09-30 | conf 0.95 | superseded | superseded_by [clm_85E7DB9BD8C5](/claim/clm_85E7DB9BD8C5.md) | [clm_28F3330C360C](/claim/clm_28F3330C360C.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815415000022/0000318154-15-000022-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,723,000,000 United States dollar | valid 2015-09-30 to 2016-03-31 | conf 0.95 | superseded | superseded_by [clm_9742AA3344DF](/claim/clm_9742AA3344DF.md) | [clm_85E7DB9BD8C5](/claim/clm_85E7DB9BD8C5.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815415000025/0000318154-15-000025-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,527,000,000 United States dollar | valid 2016-03-31 to 2016-06-30 | conf 0.95 | superseded | superseded_by [clm_293E3106D6E2](/claim/clm_293E3106D6E2.md) | [clm_9742AA3344DF](/claim/clm_9742AA3344DF.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815416000035/0000318154-16-000035-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,688,000,000 United States dollar | valid 2016-06-30 to 2016-09-30 | conf 0.95 | superseded | superseded_by [clm_E9FEE791CE06](/claim/clm_E9FEE791CE06.md) | [clm_293E3106D6E2](/claim/clm_293E3106D6E2.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815416000046/0000318154-16-000046-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,811,000,000 United States dollar | valid 2016-09-30 to 2017-03-31 | conf 0.95 | superseded | superseded_by [clm_3B1946434040](/claim/clm_3B1946434040.md) | [clm_E9FEE791CE06](/claim/clm_E9FEE791CE06.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815416000053/0000318154-16-000053-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,464,000,000 United States dollar | valid 2017-03-31 to 2017-06-30 | conf 0.95 | superseded | superseded_by [clm_8C784DFC08A6](/claim/clm_8C784DFC08A6.md) | [clm_3B1946434040](/claim/clm_3B1946434040.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815417000009/0000318154-17-000009-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,810,000,000 United States dollar | valid 2017-06-30 to 2017-09-30 | conf 0.95 | superseded | superseded_by [clm_3BAD99E25427](/claim/clm_3BAD99E25427.md) | [clm_8C784DFC08A6](/claim/clm_8C784DFC08A6.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815417000021/0000318154-17-000021-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,773,000,000 United States dollar | valid 2017-09-30 to 2018-03-31 | conf 0.95 | superseded | superseded_by [clm_756E88917872](/claim/clm_756E88917872.md) | [clm_3BAD99E25427](/claim/clm_3BAD99E25427.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815417000027/0000318154-17-000027-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,554,000,000 United States dollar | valid 2018-03-31 to 2018-06-30 | conf 0.95 | superseded | superseded_by [clm_AAF52E028DB6](/claim/clm_AAF52E028DB6.md) | [clm_756E88917872](/claim/clm_756E88917872.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815418000008/0000318154-18-000008-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,059,000,000 United States dollar | valid 2018-06-30 to 2018-09-30 | conf 0.95 | superseded | superseded_by [clm_87A5042FAB0D](/claim/clm_87A5042FAB0D.md) | [clm_AAF52E028DB6](/claim/clm_AAF52E028DB6.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815418000015/0000318154-18-000015-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,904,000,000 United States dollar | valid 2018-09-30 to 2019-03-31 | conf 0.95 | superseded | superseded_by [clm_9AD858C121AE](/claim/clm_9AD858C121AE.md) | [clm_87A5042FAB0D](/claim/clm_87A5042FAB0D.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815418000022/0000318154-18-000022-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,557,000,000 United States dollar | valid 2019-03-31 to 2019-06-30 | conf 0.95 | superseded | superseded_by [clm_0261B36A9FD9](/claim/clm_0261B36A9FD9.md) | [clm_9AD858C121AE](/claim/clm_9AD858C121AE.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815419000018/0000318154-19-000018-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,871,000,000 United States dollar | valid 2019-06-30 to 2019-09-30 | conf 0.95 | superseded | superseded_by [clm_E2FB86DE7982](/claim/clm_E2FB86DE7982.md) | [clm_0261B36A9FD9](/claim/clm_0261B36A9FD9.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815419000037/0000318154-19-000037-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,737,000,000 United States dollar | valid 2019-09-30 to 2020-03-31 | conf 0.95 | superseded | superseded_by [clm_569470E5C2FB](/claim/clm_569470E5C2FB.md) | [clm_E2FB86DE7982](/claim/clm_E2FB86DE7982.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815419000046/0000318154-19-000046-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,161,000,000 United States dollar | valid 2020-03-31 to 2020-06-30 | conf 0.95 | superseded | superseded_by [clm_CCB0903B5673](/claim/clm_CCB0903B5673.md) | [clm_569470E5C2FB](/claim/clm_569470E5C2FB.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/0000318154-20-000031-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,206,000,000 United States dollar | valid 2020-06-30 to 2020-09-30 | conf 0.95 | superseded | superseded_by [clm_A9C5A1ACE96F](/claim/clm_A9C5A1ACE96F.md) | [clm_CCB0903B5673](/claim/clm_CCB0903B5673.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/0000318154-20-000048-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,423,000,000 United States dollar | valid 2020-09-30 to 2021-03-31 | conf 0.95 | superseded | superseded_by [clm_9E8DA72630EB](/claim/clm_9E8DA72630EB.md) | [clm_A9C5A1ACE96F](/claim/clm_A9C5A1ACE96F.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/0000318154-20-000060-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 5,901,000,000 United States dollar | valid 2021-03-31 to 2021-06-30 | conf 0.95 | superseded | superseded_by [clm_C2407B4C4D35](/claim/clm_C2407B4C4D35.md) | [clm_9E8DA72630EB](/claim/clm_9E8DA72630EB.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815421000019/0000318154-21-000019-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,526,000,000 United States dollar | valid 2021-06-30 to 2021-09-30 | conf 0.95 | superseded | superseded_by [clm_77995E036FCF](/claim/clm_77995E036FCF.md) | [clm_C2407B4C4D35](/claim/clm_C2407B4C4D35.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/0000318154-21-000034-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,706,000,000 United States dollar | valid 2021-09-30 to 2022-03-31 | conf 0.95 | superseded | superseded_by [clm_7ED75B6E7D04](/claim/clm_7ED75B6E7D04.md) | [clm_77995E036FCF](/claim/clm_77995E036FCF.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/0000318154-21-000045-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,238,000,000 United States dollar | valid 2022-03-31 to 2022-06-30 | conf 0.95 | superseded | superseded_by [clm_8C035E8371E9](/claim/clm_8C035E8371E9.md) | [clm_7ED75B6E7D04](/claim/clm_7ED75B6E7D04.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/0000318154-22-000021-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,594,000,000 United States dollar | valid 2022-06-30 to 2022-09-30 | conf 0.95 | superseded | superseded_by [clm_5A9AC839EF5A](/claim/clm_5A9AC839EF5A.md) | [clm_8C035E8371E9](/claim/clm_8C035E8371E9.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/0000318154-22-000041-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,652,000,000 United States dollar | valid 2022-09-30 to 2023-03-31 | conf 0.95 | superseded | superseded_by [clm_481E925C620E](/claim/clm_481E925C620E.md) | [clm_5A9AC839EF5A](/claim/clm_5A9AC839EF5A.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815422000055/0000318154-22-000055-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,105,000,000 United States dollar | valid 2023-03-31 to 2023-06-30 | conf 0.95 | superseded | superseded_by [clm_92E3CC76739F](/claim/clm_92E3CC76739F.md) | [clm_481E925C620E](/claim/clm_481E925C620E.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815423000029/0000318154-23-000029-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,986,000,000 United States dollar | valid 2023-06-30 to 2023-09-30 | conf 0.95 | superseded | superseded_by [clm_DC8081A3AB65](/claim/clm_DC8081A3AB65.md) | [clm_92E3CC76739F](/claim/clm_92E3CC76739F.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815423000053/0000318154-23-000053-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 6,903,000,000 United States dollar | valid 2023-09-30 to 2024-03-31 | conf 0.95 | superseded | superseded_by [clm_458A0C01DCF8](/claim/clm_458A0C01DCF8.md) | [clm_DC8081A3AB65](/claim/clm_DC8081A3AB65.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815423000064/0000318154-23-000064-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 7,447,000,000 United States dollar | valid 2024-03-31 to 2024-06-30 | conf 0.95 | superseded | superseded_by [clm_CE8800B79AA0](/claim/clm_CE8800B79AA0.md) | [clm_458A0C01DCF8](/claim/clm_458A0C01DCF8.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815424000020/0000318154-24-000020-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 8,388,000,000 United States dollar | valid 2024-06-30 to 2024-09-30 | conf 0.95 | superseded | superseded_by [clm_BF9D0F8819AD](/claim/clm_BF9D0F8819AD.md) | [clm_CE8800B79AA0](/claim/clm_CE8800B79AA0.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815424000035/0000318154-24-000035-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 8,503,000,000 United States dollar | valid 2024-09-30 to 2025-03-31 | conf 0.95 | superseded | superseded_by [clm_FD554405E740](/claim/clm_FD554405E740.md) | [clm_BF9D0F8819AD](/claim/clm_BF9D0F8819AD.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815424000044/0000318154-24-000044-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 8,149,000,000 United States dollar | valid 2025-03-31 to 2025-06-30 | conf 0.95 | superseded | superseded_by [clm_DF01174105A5](/claim/clm_DF01174105A5.md) | [clm_FD554405E740](/claim/clm_FD554405E740.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/0000318154-25-000020-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 9,179,000,000 United States dollar | valid 2025-06-30 to 2025-09-30 | conf 0.95 | superseded | superseded_by [clm_56EFD8BFD444](/claim/clm_56EFD8BFD444.md) | [clm_DF01174105A5](/claim/clm_DF01174105A5.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815425000056/0000318154-25-000056-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 9,557,000,000 United States dollar | valid 2025-09-30 to 2026-03-31 | conf 0.95 | superseded | superseded_by [clm_BA3B03AF2A85](/claim/clm_BA3B03AF2A85.md) | [clm_56EFD8BFD444](/claim/clm_56EFD8BFD444.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 8,618,000,000 United States dollar | valid 2026-03-31 to 2026-06-30 | conf 0.95 | superseded | superseded_by [clm_EE4AA58E7ACE](/claim/clm_EE4AA58E7ACE.md) | [clm_BA3B03AF2A85](/claim/clm_BA3B03AF2A85.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/0000318154-26-000057-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 10,054,000,000 United States dollar | valid 2026-06-30 to 2026-09-30 | conf 0.95 | superseded | superseded_by [clm_985DF46177C9](/claim/clm_985DF46177C9.md) | [clm_EE4AA58E7ACE](/claim/clm_EE4AA58E7ACE.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm
- [Amgen](/record/amgen.md) | quarterly_revenue | 10,365,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_985DF46177C9](/claim/clm_985DF46177C9.md)
  sources: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm

## What replaced what

- $3.76 billion (2008-06-30 to 2008-09-30, [clm_17341E32AFF6](/claim/clm_17341E32AFF6.md)) was replaced by $3.88 billion from 2008-09-30 ([clm_D6A6F66C922D](/claim/clm_D6A6F66C922D.md))
- $3.88 billion (2008-09-30 to 2009-03-31, [clm_D6A6F66C922D](/claim/clm_D6A6F66C922D.md)) was replaced by $3.31 billion from 2009-03-31 ([clm_E30E52778B73](/claim/clm_E30E52778B73.md))
- $3.31 billion (2009-03-31 to 2009-06-30, [clm_E30E52778B73](/claim/clm_E30E52778B73.md)) was replaced by $3.71 billion from 2009-06-30 ([clm_C0FD4A4DBDE5](/claim/clm_C0FD4A4DBDE5.md))
- $3.71 billion (2009-06-30 to 2009-09-30, [clm_C0FD4A4DBDE5](/claim/clm_C0FD4A4DBDE5.md)) was replaced by $3.81 billion from 2009-09-30 ([clm_AC30B5A349EC](/claim/clm_AC30B5A349EC.md))
- $3.81 billion (2009-09-30 to 2010-03-31, [clm_AC30B5A349EC](/claim/clm_AC30B5A349EC.md)) was replaced by $3.59 billion from 2010-03-31 ([clm_0468DD568B92](/claim/clm_0468DD568B92.md))
- $3.59 billion (2010-03-31 to 2010-06-30, [clm_0468DD568B92](/claim/clm_0468DD568B92.md)) was replaced by $3.8 billion from 2010-06-30 ([clm_623DCF66B2AC](/claim/clm_623DCF66B2AC.md))
- $3.8 billion (2010-06-30 to 2010-09-30, [clm_623DCF66B2AC](/claim/clm_623DCF66B2AC.md)) was replaced by $3.82 billion from 2010-09-30 ([clm_1E3DCB2075FA](/claim/clm_1E3DCB2075FA.md))
- $3.82 billion (2010-09-30 to 2011-03-31, [clm_1E3DCB2075FA](/claim/clm_1E3DCB2075FA.md)) was replaced by $3.71 billion from 2011-03-31 ([clm_5C7EB0130754](/claim/clm_5C7EB0130754.md))
- $3.71 billion (2011-03-31 to 2011-06-30, [clm_5C7EB0130754](/claim/clm_5C7EB0130754.md)) was replaced by $3.96 billion from 2011-06-30 ([clm_5FE67E316722](/claim/clm_5FE67E316722.md))
- $3.96 billion (2011-06-30 to 2011-09-30, [clm_5FE67E316722](/claim/clm_5FE67E316722.md)) was replaced by $3.94 billion from 2011-09-30 ([clm_296C33E5B63E](/claim/clm_296C33E5B63E.md))
- $3.94 billion (2011-09-30 to 2012-03-31, [clm_296C33E5B63E](/claim/clm_296C33E5B63E.md)) was replaced by $4.05 billion from 2012-03-31 ([clm_2763B8997D8B](/claim/clm_2763B8997D8B.md))
- $4.05 billion (2012-03-31 to 2012-06-30, [clm_2763B8997D8B](/claim/clm_2763B8997D8B.md)) was replaced by $4.48 billion from 2012-06-30 ([clm_D4DC1453EF41](/claim/clm_D4DC1453EF41.md))
- $4.48 billion (2012-06-30 to 2012-09-30, [clm_D4DC1453EF41](/claim/clm_D4DC1453EF41.md)) was replaced by $4.32 billion from 2012-09-30 ([clm_5BA2730341DC](/claim/clm_5BA2730341DC.md))
- $4.32 billion (2012-09-30 to 2013-03-31, [clm_5BA2730341DC](/claim/clm_5BA2730341DC.md)) was replaced by $4.24 billion from 2013-03-31 ([clm_4DC2460750E0](/claim/clm_4DC2460750E0.md))
- $4.24 billion (2013-03-31 to 2013-06-30, [clm_4DC2460750E0](/claim/clm_4DC2460750E0.md)) was replaced by $4.68 billion from 2013-06-30 ([clm_B14B41207FDF](/claim/clm_B14B41207FDF.md))
- $4.68 billion (2013-06-30 to 2013-09-30, [clm_B14B41207FDF](/claim/clm_B14B41207FDF.md)) was replaced by $4.75 billion from 2013-09-30 ([clm_3033018610D0](/claim/clm_3033018610D0.md))
- $4.75 billion (2013-09-30 to 2014-03-31, [clm_3033018610D0](/claim/clm_3033018610D0.md)) was replaced by $4.52 billion from 2014-03-31 ([clm_4A26C5460842](/claim/clm_4A26C5460842.md))
- $4.52 billion (2014-03-31 to 2014-06-30, [clm_4A26C5460842](/claim/clm_4A26C5460842.md)) was replaced by $5.18 billion from 2014-06-30 ([clm_F203C4084F80](/claim/clm_F203C4084F80.md))
- $5.18 billion (2014-06-30 to 2014-09-30, [clm_F203C4084F80](/claim/clm_F203C4084F80.md)) was replaced by $5.03 billion from 2014-09-30 ([clm_FE2BDD289F38](/claim/clm_FE2BDD289F38.md))
- $5.03 billion (2014-09-30 to 2015-03-31, [clm_FE2BDD289F38](/claim/clm_FE2BDD289F38.md)) was replaced by $5.03 billion from 2015-03-31 ([clm_C0A999C2E5DE](/claim/clm_C0A999C2E5DE.md))
- $5.03 billion (2015-03-31 to 2015-06-30, [clm_C0A999C2E5DE](/claim/clm_C0A999C2E5DE.md)) was replaced by $5.37 billion from 2015-06-30 ([clm_28F3330C360C](/claim/clm_28F3330C360C.md))
- $5.37 billion (2015-06-30 to 2015-09-30, [clm_28F3330C360C](/claim/clm_28F3330C360C.md)) was replaced by $5.72 billion from 2015-09-30 ([clm_85E7DB9BD8C5](/claim/clm_85E7DB9BD8C5.md))
- $5.72 billion (2015-09-30 to 2016-03-31, [clm_85E7DB9BD8C5](/claim/clm_85E7DB9BD8C5.md)) was replaced by $5.53 billion from 2016-03-31 ([clm_9742AA3344DF](/claim/clm_9742AA3344DF.md))
- $5.53 billion (2016-03-31 to 2016-06-30, [clm_9742AA3344DF](/claim/clm_9742AA3344DF.md)) was replaced by $5.69 billion from 2016-06-30 ([clm_293E3106D6E2](/claim/clm_293E3106D6E2.md))
- $5.69 billion (2016-06-30 to 2016-09-30, [clm_293E3106D6E2](/claim/clm_293E3106D6E2.md)) was replaced by $5.81 billion from 2016-09-30 ([clm_E9FEE791CE06](/claim/clm_E9FEE791CE06.md))
- $5.81 billion (2016-09-30 to 2017-03-31, [clm_E9FEE791CE06](/claim/clm_E9FEE791CE06.md)) was replaced by $5.46 billion from 2017-03-31 ([clm_3B1946434040](/claim/clm_3B1946434040.md))
- $5.46 billion (2017-03-31 to 2017-06-30, [clm_3B1946434040](/claim/clm_3B1946434040.md)) was replaced by $5.81 billion from 2017-06-30 ([clm_8C784DFC08A6](/claim/clm_8C784DFC08A6.md))
- $5.81 billion (2017-06-30 to 2017-09-30, [clm_8C784DFC08A6](/claim/clm_8C784DFC08A6.md)) was replaced by $5.77 billion from 2017-09-30 ([clm_3BAD99E25427](/claim/clm_3BAD99E25427.md))
- $5.77 billion (2017-09-30 to 2018-03-31, [clm_3BAD99E25427](/claim/clm_3BAD99E25427.md)) was replaced by $5.55 billion from 2018-03-31 ([clm_756E88917872](/claim/clm_756E88917872.md))
- $5.55 billion (2018-03-31 to 2018-06-30, [clm_756E88917872](/claim/clm_756E88917872.md)) was replaced by $6.06 billion from 2018-06-30 ([clm_AAF52E028DB6](/claim/clm_AAF52E028DB6.md))
- $6.06 billion (2018-06-30 to 2018-09-30, [clm_AAF52E028DB6](/claim/clm_AAF52E028DB6.md)) was replaced by $5.9 billion from 2018-09-30 ([clm_87A5042FAB0D](/claim/clm_87A5042FAB0D.md))
- $5.9 billion (2018-09-30 to 2019-03-31, [clm_87A5042FAB0D](/claim/clm_87A5042FAB0D.md)) was replaced by $5.56 billion from 2019-03-31 ([clm_9AD858C121AE](/claim/clm_9AD858C121AE.md))
- $5.56 billion (2019-03-31 to 2019-06-30, [clm_9AD858C121AE](/claim/clm_9AD858C121AE.md)) was replaced by $5.87 billion from 2019-06-30 ([clm_0261B36A9FD9](/claim/clm_0261B36A9FD9.md))
- $5.87 billion (2019-06-30 to 2019-09-30, [clm_0261B36A9FD9](/claim/clm_0261B36A9FD9.md)) was replaced by $5.74 billion from 2019-09-30 ([clm_E2FB86DE7982](/claim/clm_E2FB86DE7982.md))
- $5.74 billion (2019-09-30 to 2020-03-31, [clm_E2FB86DE7982](/claim/clm_E2FB86DE7982.md)) was replaced by $6.16 billion from 2020-03-31 ([clm_569470E5C2FB](/claim/clm_569470E5C2FB.md))
- $6.16 billion (2020-03-31 to 2020-06-30, [clm_569470E5C2FB](/claim/clm_569470E5C2FB.md)) was replaced by $6.21 billion from 2020-06-30 ([clm_CCB0903B5673](/claim/clm_CCB0903B5673.md))
- $6.21 billion (2020-06-30 to 2020-09-30, [clm_CCB0903B5673](/claim/clm_CCB0903B5673.md)) was replaced by $6.42 billion from 2020-09-30 ([clm_A9C5A1ACE96F](/claim/clm_A9C5A1ACE96F.md))
- $6.42 billion (2020-09-30 to 2021-03-31, [clm_A9C5A1ACE96F](/claim/clm_A9C5A1ACE96F.md)) was replaced by $5.9 billion from 2021-03-31 ([clm_9E8DA72630EB](/claim/clm_9E8DA72630EB.md))
- $5.9 billion (2021-03-31 to 2021-06-30, [clm_9E8DA72630EB](/claim/clm_9E8DA72630EB.md)) was replaced by $6.53 billion from 2021-06-30 ([clm_C2407B4C4D35](/claim/clm_C2407B4C4D35.md))
- $6.53 billion (2021-06-30 to 2021-09-30, [clm_C2407B4C4D35](/claim/clm_C2407B4C4D35.md)) was replaced by $6.71 billion from 2021-09-30 ([clm_77995E036FCF](/claim/clm_77995E036FCF.md))
- $6.71 billion (2021-09-30 to 2022-03-31, [clm_77995E036FCF](/claim/clm_77995E036FCF.md)) was replaced by $6.24 billion from 2022-03-31 ([clm_7ED75B6E7D04](/claim/clm_7ED75B6E7D04.md))
- $6.24 billion (2022-03-31 to 2022-06-30, [clm_7ED75B6E7D04](/claim/clm_7ED75B6E7D04.md)) was replaced by $6.59 billion from 2022-06-30 ([clm_8C035E8371E9](/claim/clm_8C035E8371E9.md))
- $6.59 billion (2022-06-30 to 2022-09-30, [clm_8C035E8371E9](/claim/clm_8C035E8371E9.md)) was replaced by $6.65 billion from 2022-09-30 ([clm_5A9AC839EF5A](/claim/clm_5A9AC839EF5A.md))
- $6.65 billion (2022-09-30 to 2023-03-31, [clm_5A9AC839EF5A](/claim/clm_5A9AC839EF5A.md)) was replaced by $6.11 billion from 2023-03-31 ([clm_481E925C620E](/claim/clm_481E925C620E.md))
- $6.11 billion (2023-03-31 to 2023-06-30, [clm_481E925C620E](/claim/clm_481E925C620E.md)) was replaced by $6.99 billion from 2023-06-30 ([clm_92E3CC76739F](/claim/clm_92E3CC76739F.md))
- $6.99 billion (2023-06-30 to 2023-09-30, [clm_92E3CC76739F](/claim/clm_92E3CC76739F.md)) was replaced by $6.9 billion from 2023-09-30 ([clm_DC8081A3AB65](/claim/clm_DC8081A3AB65.md))
- $6.9 billion (2023-09-30 to 2024-03-31, [clm_DC8081A3AB65](/claim/clm_DC8081A3AB65.md)) was replaced by $7.45 billion from 2024-03-31 ([clm_458A0C01DCF8](/claim/clm_458A0C01DCF8.md))
- $7.45 billion (2024-03-31 to 2024-06-30, [clm_458A0C01DCF8](/claim/clm_458A0C01DCF8.md)) was replaced by $8.39 billion from 2024-06-30 ([clm_CE8800B79AA0](/claim/clm_CE8800B79AA0.md))
- $8.39 billion (2024-06-30 to 2024-09-30, [clm_CE8800B79AA0](/claim/clm_CE8800B79AA0.md)) was replaced by $8.5 billion from 2024-09-30 ([clm_BF9D0F8819AD](/claim/clm_BF9D0F8819AD.md))
- $8.5 billion (2024-09-30 to 2025-03-31, [clm_BF9D0F8819AD](/claim/clm_BF9D0F8819AD.md)) was replaced by $8.15 billion from 2025-03-31 ([clm_FD554405E740](/claim/clm_FD554405E740.md))
- $8.15 billion (2025-03-31 to 2025-06-30, [clm_FD554405E740](/claim/clm_FD554405E740.md)) was replaced by $9.18 billion from 2025-06-30 ([clm_DF01174105A5](/claim/clm_DF01174105A5.md))
- $9.18 billion (2025-06-30 to 2025-09-30, [clm_DF01174105A5](/claim/clm_DF01174105A5.md)) was replaced by $9.56 billion from 2025-09-30 ([clm_56EFD8BFD444](/claim/clm_56EFD8BFD444.md))
- $9.56 billion (2025-09-30 to 2026-03-31, [clm_56EFD8BFD444](/claim/clm_56EFD8BFD444.md)) was replaced by $8.62 billion from 2026-03-31 ([clm_BA3B03AF2A85](/claim/clm_BA3B03AF2A85.md))
- $8.62 billion (2026-03-31 to 2026-06-30, [clm_BA3B03AF2A85](/claim/clm_BA3B03AF2A85.md)) was replaced by $10.05 billion from 2026-06-30 ([clm_EE4AA58E7ACE](/claim/clm_EE4AA58E7ACE.md))
- $10.05 billion (2026-06-30 to 2026-09-30, [clm_EE4AA58E7ACE](/claim/clm_EE4AA58E7ACE.md)) was replaced by $10.37 billion from 2026-09-30 ([clm_985DF46177C9](/claim/clm_985DF46177C9.md))

## Questions this record answers

### What is Amgen's current quarterly revenue?

$10.37 billion, dated September 30, 2026, from a primary source (sec.gov). The record asserts this claim as of November 9, 2026 (status valid, confidence 0.95).

### When did Amgen's quarterly revenue last change?

The latest value on the record is $10.37 billion, dated September 30, 2026; before it the record holds $10.05 billion, dated June 30, 2026 and closed on September 30, 2026.

### What was Amgen's quarterly revenue before $10.37 billion?

$10.05 billion, valid from June 30, 2026 to September 30, 2026 (status superseded), from a primary source (sec.gov).


## Read on

- This page: /record/amgen/quarterly_revenue (markdown: /record/amgen/quarterly_revenue.md)
- Entity twin: /record/amgen.md · timeline: /timelines/amgen.md
- Every company's quarterly revenue: /facts/quarterly_revenue.md

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.